# A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients

> **NCT02608437** · PHASE1 · UNKNOWN · sponsor: **Italian Network for Tumor Biotherapy Foundation** · enrollment: 19 (estimated)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** SGI-110
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT02608437
- **Lead sponsor:** Italian Network for Tumor Biotherapy Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-10
- **Primary completion:** 2016-10
- **Final completion:** 2018-10
- **Target enrollment:** 19 (ESTIMATED)
- **Last updated:** 2015-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02608437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02608437, "A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02608437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*